Anti-IgE Monoclonal Antibody (Omalizumab) is effective in Treating Bullous Pemphigoid and Its Effects on Soluble CD200

Clinical Laboratory

Volumn 60, Issue 3, 2014, Pages 523-524

  Yalcin, Arzu Didem ^a   Genc, Gizem Esra ^b   Celik, Betul ^c   Gumuslu, Saadet ^b  

^a ACADEMIA SINICA   (Taiwan)

^b AKDENIZ UNIVERSITY   (Turkey)

^c MH Antalya Training and Research Hospital   (Turkey)

Author keywords

Anti IgE monoclonal antibody; Bullous pemphigoid; Omalizumab

Indexed keywords

CD200 ANTIGEN; OMALIZUMAB;

ABDOMEN; ADULT; ARTICLE; BODY SURFACE; BULLOUS PEMPHIGOID; CASE REPORT; DISEASE EXACERBATION; DRUG EFFECT; FOLLOW UP; HUMAN; LEG; MALE; THORAX; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD; HUMANS; MALE; PEMPHIGOID, BULLOUS;

EID: 84887355615     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2013.130642     Document Type: Article

References (7)

1. Fairley JA, London VA, Kim GH, Woodley DT. Successful Treatment of Bullous Pemphigoid With Omalizumab. Arch Dermatol 2012;148(11):1241-3 doi:10.1001/archdermatol.2012.1604.
2. Yalcin AD, Bisgin A, Gorczynski RM. IL-8, IL10, TGF-β and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamation 2012, doi:10.1155/2012/720976.
3. Chang TW, Shiung YY. Anti IgE as a mast cell stabilizing therapeutic agent. J Allergy Clin Immunol 2006;117:1203-12. (Pubitemid 43795763)
4. Yalcin AD, Bisgin A, Cetinkaya R, et al. Clinical Course and Side Effects of Omalizumab in Patients with Severe Persistent Asthma. Clin Lab 2013;59:71-7.
5. Yalcin AD, Ucar S, Gumuslu S, Strauss L. Effects of Omalizumab on Eosinophil Cationic Peptid, 25-Hydroxyvitamin-D, IL-1β, and sCD200 in a cases of Samter's syndrome: 36 Months follow-up. Immunopharmacology And Immunotoxicology DOI:10.3109/08923973.2013.811598.
6. Yalcin AD, Cilli A, Bisgin A, Strauss L, Herth F. Omalizumab is effective in treating severe asthma in patients with severe cadiovascular complications and effects on sCD200, d- dimer, CXCL8 and IL-1β levels. Expert Opinion on Biological Therapy. DOI:10.1517/14712598.2013.819338.
7. Yalcin AD, Karakas AA, Soykam G, et al. A Case of Toxic Epidermal Necrolysis with Diverse Etiologies: Successful Treatment with Intravenous Immunoglobulin and Pulse Prednisolone and Effects on sTRAIL and sCD200 Levels. Clin Lab 2013;59. DOI: 10.7754/Clin.Lab.2012.120814.